Thursday, April 17, 2014

Expecting A Breakout Year For OxySure

By Jason Napodano, CFA

- Revenue growth in 2013 was up 567%.
- CE Mark in Europe could double sales in 2014.
- Expect strong military orders later this year.
- Stock trading at less than 5x our 2016 EPS estimate.

Please read the full article on Seeking-Alpha: LINK

Any questions about this article of any other BioNapCFA article, Book-A-Call!

Wednesday, April 16, 2014

Cynapsus Therapeutics Still A Top Pick

By Jason Napodano, CFA

- The following is a transcript of an interview with Zacks' Sr. Biotech analyst Jason Napodano.
- The recent financing pulled in $23+ million in cash and looks to be enough to fund operations and development of APL-130277 through the NDA filing.
- Jason continues to believe Cynapsus shares represent a compelling value for investors.
- Target price is $2.15 per share, or 250% upside from today.

Cynapsus Therapeutics (OTCQX:CYNAF) shares have nearly round-tripped since Zacks Small-Cap Research ("ZSCR") biotech analyst Jason Napodano, CFA ("JN") first initiated coverage on the stock last year. Back in June 2013, Jason called Cynapsus, "An undiscovered gem" and recommended investors buy the shares at $0.30 per share. In February 2014, writing for Zacks, Jason called the company, "One of our best ideas," reiterating his bullish stance at $0.78. Last week, Cynapsus announced they were raising cash to the tune of $15 to $25 million, and that hit the shares hard. The deal was priced at CAD$0.65 ($0.595 per share). With the deal now completed, and $23.2 million of new cash in the bank, we thought it was a good time to circle back with Jason and get his take on Cynapsus for investors today.

Please read the interview on Seeking-Alpha: LINK

Any questions about this article of any other BioNapCFA article, Book-A-Call!

Tuesday, April 15, 2014

Immune Pharma Tackling Orphan Disease Bullous Pemphigoid

By Jason Napodano, CFA & David Bautz, PhD

- Bertilimumab is a first-in-class fully human monoclonal antibody that is directed against eotaxin-1, a potent chemoattractant and activator of eosinophils.
- Eosinophils are implicated in the inflammatory changes seen in various inflammatory disorders such as irritable bowel disease (IBD), asthma, and dermatological diseases such as bullous pemphigoid (BP).
- BP is an orphan dermatological disease that affects approximately 12,000 people in the U.S. each year.
- Eotaxin-1 plays a role in the recruitment of inflammatory cells to skin lesions in patients with BP and represents a novel therapeutic target for this disease.

Please read the article on Seeking-Alpha: LINK

Any questions about this article of any other BioNapCFA article, Book-A-Call!